The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

被引：58

作者：

Tzavara, ET ^{[1
]}

Perry, KW ^{[1
]}

Rodriguez, DE ^{[1
]}

Bymaster, FP ^{[1
]}

Nomikos, GG ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Neurosci Discovery Res, Indianapolis, IN 46285 USA

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2001年 / 426卷 / 03期

关键词：

microdialysis; norepinephrine; SR141716A;

D O I：

10.1016/S0014-2999(01)01228-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effects of the selective cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide-hydrochloride (SR141716A) on extracellular concentrations of norepinephrine and 5-hydroxytryptamine (5-HT) were assessed by in vivo microdialysis in the anterior hypothalamus of freely moving rats. SR14716A (0.3, 1, 3 mg/kg, i.p.) dose-dependently increased norepinephrine efflux to about 300% of baseline, without affecting 5-HT levels. This increase in norepinephrine outflow could play an important role in the pharmacological and potentially therapeutic actions of SR141716A. (C) 2001 Published by Elsevier Science B.V.

引用

页码：R3 / R4

页数：2

共 8 条

[1] Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function [J].

Alonso, R ;

Voutsinos, B ;

Fournier, M ;

Labie, C ;

Steinberg, R ;

Souilhac, J ;

Le Fur, G ;

Soubrie, P .

NEUROSCIENCE, 1999, 91 (02) :607-620

[2] Behavioral effects of cannabinoid agents in animals [J].

Chaperon, F ;

Thiébot, MH .

CRITICAL REVIEWS IN NEUROBIOLOGY, 1999, 13 (03) :243-281

[3] Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A [J].

Gessa, GL ;

Casu, MA ;

Carta, G ;

Mascia, MS .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 355 (2-3) :119-124

[4] Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices [J].

Gifford, AN ;

Samiian, L ;

Gatley, SJ ;

Ashby, CR .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 324 (2-3) :187-192

[5] Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain [J].

Kathmann, M ;

Bauer, U ;

Schlicker, E ;

Göthert, M .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (06) :466-470

[6] Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats [J].

Perry, KW ;

Fuller, RW .

JOURNAL OF NEURAL TRANSMISSION, 1997, 104 (8-9) :953-966

[7] SR141716A, A POTENT AND SELECTIVE ANTAGONIST OF THE BRAIN CANNABINOID RECEPTOR [J].

RINALDICARMONA, M ;

BARTH, F ;

HEAULME, M ;

SHIRE, D ;

CALANDRA, B ;

CONGY, C ;

MARTINEZ, S ;

MARUANI, J ;

NELIAT, G ;

CAPUT, D ;

FERRARA, P ;

SOUBRIE, P ;

BRELIERE, JC ;

LEFUR, G .

FEBS LETTERS, 1994, 350 (2-3) :240-244

[8] Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum [J].

Tzavara, ET ;

Valjent, E ;

Firmo, C ;

Mas, M ;

Beslot, F ;

Defer, N ;

Roques, BP ;

Hanoune, J ;

Maldonado, R .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (03) :1038-1046

← 1 →